P53 Suppression
P53 Suppression - Related Videos
08:34
The Measurement and Treatment of Suppression in Amblyopia
0 Views •
Cited by 54 •
2012
Amblyopia is a developmental disorder of the visual cortex that is often accompanied by strong suppression of one eye. We present a new technique for measuring and treating interocular suppression in patients with amblyopia that can be deployed using virtual reality goggles or a portable iPod Touch device.
04:56
Detection of Aggregation-Prone Behavior in Mutant P53 V157F Breast Cancer Cells Using Multipoint Thioflavin T Fluorescence
0 Views •
2025
Hs578T breast cancer cells harboring the p53 V157F mutation exhibit significantly higher Thioflavin T fluorescence compared to MCF7 cells, indicating enhanced protein aggregation. Multipoint fluorescence measurements improve detection accuracy and reliability in identifying β-sheet-rich aggregates, underscoring the importance of aggregation-prone p53 mutations in cancer research and the development of therapeutic strategies.
04:29
Visualizing Transcriptional Suppression in Virus-Infected Cells
0 Views •
2026
Source: Kalveram, B. et al. Using Click Chemistry to Measure the Effect of Viral Infection on Host-Cell RNA Synthesis. J. Vis. Exp. (2013)This video demonstrates the use of click chemistry and fluorescence microscopy to visualize nascent RNA transcription in mammalian cells. It highlights how viral infection suppresses host transcription by comparing fluorescent signals between infected and control cells.
14:01
Human In Vitro Suppression as Screening Tool for the Recognition of an Early State of Immune Imbalance
0 Views •
2011
Tregs are potent suppressors of the immune system. There is a lack of unique surface markers to define them, hence, definitions of Tregs are primarily functional. Here we describe an optimized in vitro assay capable of identifying immune imbalance in subjects at risk to develop T1D.
10:55
Purification of Ubiquitinated p53 Proteins from Mammalian Cells
0 Views •
Cited by 1 •
2022
The protocol describes a step-by-step method to purify ubiquitinated proteins from mammalian cells using the p53 tumor suppressor protein as an example. Ubiquitinated p53 proteins were purified from cells under stringent nondenaturing and denaturing conditions.
FAQs
MDM2 suppresses p53 through a targeted degradation pathway. After binding p53, MDM2 promotes addition of ubiquitin, a molecular tag associated here with proteasomal destruction. This lowers the amount of p53 available to act in the cell. The mechanism links regulator activity directly to the abundance of the tumor-suppressor protein.
MDM4 acts differently from MDM2: its key effect is inhibition of p53-dependent transcription rather than promotion of proteasomal degradation. Consequently, p53 may remain present while its transcriptional output is reduced. Distinguishing these mechanisms is important when interpreting why p53 signaling is weak and when considering which negative regulatory interaction a therapy should target.
Mutations or other regulatory changes can weaken the p53 pathway without relying solely on increased MDM2 or MDM4 activity. Such defects may interfere with the pathway's ability to produce an effective stress response. In cancer biology, separating altered regulation from altered protein function helps explain why p53 suppression can persist through different molecular routes.
Persistent p53 suppression changes the consequences of cellular damage: cells that would otherwise undergo cell-cycle arrest or apoptosis can continue supporting tumor development. The same failure can contribute to treatment resistance, because a weakened p53 response may reduce the cellular effects that therapy is intended to provoke. This makes pathway status relevant to cancer interpretation.
A focused analysis can compare p53 activity or abundance with the status of MDM2, MDM4, and possible mutations or regulatory changes. This framework distinguishes reduced protein availability from transcriptional inhibition or broader pathway defects. The resulting molecular profile can help connect a suppressed response with tumor behavior and guide selection of relevant biomarkers.
Because suppression can arise through several regulatory routes, useful biomarkers may need to reflect more than p53 abundance alone. Examining negative regulators and pathway defects can provide a fuller picture of signaling status. Such information may help identify tumors with impaired p53 responses and support interpretation of disease behavior or treatment resistance.
One strategy is to block negative regulators of p53, including mechanisms involving MDM2 or MDM4. Another is to target defective regulatory pathways when suppression results from broader molecular changes. The goal is to restore p53 signaling rather than simply measure its loss, potentially improving understanding of how tumors respond to treatment.